Nuclear medicine therapy of differentiated thyroid cancer: Status quo;Nuklearmedizinische Therapie und Nachsorge des differenzierten Schilddrüsenkarzinoms: Status quo

Onkologe

Volumn 16, Issue 7, 2010, Pages 678-689

  Dietlein, M ^a   Luster, M ^b   Reiners, C ^c  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Differentiated thyroid cancer; Iodine 131 ablation; Radioiodine treatment; rhTSH; Risk stratification

Indexed keywords

RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN;

BONE MARROW TOXICITY; CANCER REGRESSION; DISTANT METASTASIS; DOSIMETRY; HUMAN; HYPOTHYROIDISM; LUNG METASTASIS; LYMPH NODE DISSECTION; PROGNOSIS; RADIATION EXPOSURE; REVIEW; SUBTOTAL THYROIDECTOMY; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY;

EID: 77955811149     PISSN: 09478965     EISSN: 14330415     Source Type: Journal    
DOI: 10.1007/s00761-010-1869-8     Document Type: Review

References (31)

1. Reiners C (2006) Diagnostik, Therapie und Nachsorge des Schilddrüsenkarzinoms, 2. Aufl. Unimed, Bremen
2. Dietlein M, Luster M, Reiners C (2010) Differenziertes Schilddrüsenkarzinom: risikoadaptierte Behandlung und Nachsorge, Update 2010. Thieme-Refresher Onkologie 3(1):R1-R24
3. Sobin LH, Wittekind C (2002) TNM classification of malignant tumours, 6th edn. Wiley-Liss, New York, pp 52-56
4. Wittekind C, Greene FL, Henson DE et al (2003) TNM supplement. A commentary on uniform use, 3rd edn. Wiley-Liss, New York, p 138
5. Dietlein M, Dressler J, Eschner W et al (2007) Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 3). Nuklearmedizin 46:213-219 (Pubitemid 47612288)
6. Dietlein M, Dressler J, Eschner W et al (2007) Guideline for 131I whole-body scintigraphy for differentiated thyroid cancer (version 3). Nuklearmedizin 46:206-212
7. Pacini F, Schlumberger M, Dralle H et al (2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787-803
8. Sawka AM, Thephamongkhol K, Brouwers M et al (2004) Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 89:3668-3676
9. Sawka AM, Brierley JD, Tsang RW et al (2008) An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin N Am 37:457-480
10. Park EK, Chung JK, Lim IH et al (2009) Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans. Eur J Nucl Med Mol Imaging 36:172-179
11. Pelizzo MR, Boschin IM, Toniato A et al (2004) Natural history, diagnosis, treatment and outcome of papillary thyroid microcarcinoma (PTMC): a monoinstitutional 12-year experience. Nucl Med Commun 25:547-552
12. Machens A, Holzhausen HJ, Dralle H (2005) The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer 103:2269-2273
13. Lundh C, Lindencrona U, Postgard P et al (2009) Radiation-induced thyroid stunning: differential effects of 123I, 131I, 99mTc, and 211At on iodide transport and NIS mRNA expression in cultured thyroid cells. J Nucl Med 50:1161-1167
14. Dralle H, Luster M (2010) Thyrotrophin alpha (rhTSH). Radioiodablation in euthyreoter Stoffwechsellage bei Patienten mit differenziertem Schilddrüsenkarzinom. Thieme Drug Report 4:1-12
15. Pacini F, Ladenson PW, Schlumberger M et al (2006) Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 91:926-932
16. Elisei R, Schlumberger M, Driedger A et al (2009) Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metab 94:4171-4179
17. Cooper DS, Doherty GM, Haugen BR et al (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214
18. Pacini F, Castagna MG, Brilli L, Pentheroudakis G (2009) ESMO Guidelines Working Group. Differentiated thyroid cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20 (Suppl 4):143-146
19. Luster M, Clarke SE, Dietlein M et al (2008) Guidelines for radioiodine treatment of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 35:1941-1959
20. European Medicines Agency (EMEA) (2009) Committee for medicinal products for human use. Post-authorisation summary of positive opinion for thyrogen. EMEA/CHMP/745393/2009
21. Haenscheid H, Lassmann M, Luster M et al (2006) Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 47:648-654
22. Rosário PW, Borges MA, Purisch S (2008) Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity. J Nucl Med 49:1776-1782
23. Rosario PW, Santos Salles D, Purisch S (2009) Area under the curve of TSH after levothyroxine withdrawal versus administration of recombinant human TSH (rhTSH): possible implications for tumor growth. Arq Bras Endocrinol Metab 53/6:767-770
24. Luster M, Lippi F, Jarzab B et al (2005) rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer 12:49-64 (Pubitemid 40477087)
25. Jarzab B, Handkiewicz-Junak D, Roskosz J et al (2003) Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid cancer: single-center study of 54 patients. Eur J Nucl Med Mol Imaging 30:1077-1086
26. Luster M, Sherman SI, Skarulis MC et al (2003) Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone (rhTSH) and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imaging 30:1371-1377
27. Simon D, Körber C, Krausch M et al (2002) Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med Mol Imaging 29:775-782
28. Rubino C, Vathaire F de, Dottorini ME et al (2003) Second primary malignancy in thyroid cancer patients. Br J Cancer 89:1638-1644
29. Gilliland FD, Hunt WC, Morris DM, Key CR (1997) Prognostic factors for thyroid carcinoma: a population-based study of 15,698 cases for the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer 79:564-573
30. Brown AP, Chen J, Hitchcock YJ et al (2008) The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 93:504-515
31. Düren C, Dietlein M, Luster M et al (2010) The use of thyrogen in the treatment of differentiated thyroid carcinoma: an intraindividual comparison of clinical effects and economic aspects. Exp Clin Endocrinol Diabetes (in press)